Ana Ugarte
College of the Holy Cross(US)
Publications by Year
Research Areas
Phosphodiesterase function and regulation, Histone Deacetylase Inhibitors Research, Cholinesterase and Neurodegenerative Diseases, Epigenetics and DNA Methylation, Alzheimer's disease research and treatments
Most-Cited Works
- → Discovery of first-in-class reversible dual small molecule inhibitors against G9a and DNMTs in hematological malignancies(2017)166 cited
- → Trimethylamine-N-Oxide (TMAO) Predicts Cardiovascular Mortality in Peripheral Artery Disease(2019)156 cited
- → Decreased levels of guanosine 3′, 5′‐monophosphate (cGMP) in cerebrospinal fluid (CSF) are associated with cognitive decline and amyloid pathology in Alzheimer's disease(2014)108 cited
- → A First-in-Class Small-Molecule that Acts as a Dual Inhibitor of HDAC and PDE5 and that Rescues Hippocampal Synaptic Impairment in Alzheimer’s Disease Mice(2016)103 cited
- → Design, Synthesis, and Biological Evaluation of First-in-Class Dual Acting Histone Deacetylases (HDACs) and Phosphodiesterase 5 (PDE5) Inhibitors for the Treatment of Alzheimer’s Disease(2016)85 cited
- → The monoacylglycerol lipase inhibitor JZL184 is neuroprotective and alters glial cell phenotype in the chronic MPTP mouse model(2014)85 cited
- → Design, synthesis, biological evaluation and in vivo testing of dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors for the treatment of Alzheimer's disease(2018)67 cited
- → Concomitant histone deacetylase and phosphodiesterase 5 inhibition synergistically prevents the disruption in synaptic plasticity and it reverses cognitive impairment in a mouse model of Alzheimer’s disease(2015)66 cited
- → Discovery of Reversible DNA Methyltransferase and Lysine Methyltransferase G9a Inhibitors with Antitumoral in Vivo Efficacy(2018)61 cited
- → Pharmacokinetic investigation of sildenafil using positron emission tomography and determination of its effect on cerebrospinal fluid cGMP levels(2015)48 cited